by6pzve | Knowledge4COVID-19

Property	Value
is ?:annotates of	<https://research.tib.eu/covid-19/entity/6by6pzve_hasAnnotation_C0013227>
?:creator	<https://research.tib.eu/covid-19/entity/Finsterer%2C_J.>
?:doi	10.1007/s13760-020-01551-8
?:doi	<https://research.tib.eu/covid-19/entity/10.1007/s13760-020-01551-8>
?:journal	Acta_Neurol_Belg
?:license	no-cc
?:pdf_json_files	document_parses/pdf_json/be3a4b3e6db690a97b231f01585f906891e650a1.json
?:pmc_json_files	document_parses/pmc_json/PMC7680670.xml.json
?:pmcid	<https://research.tib.eu/covid-19/entity/PMC7680670>
?:pmid	<https://research.tib.eu/covid-19/entity/33225405.0>
?:pmid	33225405.0
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
?:sha_id	<https://research.tib.eu/covid-19/entity/be3a4b3e6db690a97b231f01585f906891e650a1>
?:source	Medline; PMC
?:title	Myotoxic drugs and immunodeficiency may contribute to the poor outcome of COVID-19 patients with myotonic dystrophy
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:year	2020-11-23

Metadata

Anon_0

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://purl.org/net/provenance/ns#DataItem>

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://www.w3.org/2004/03/trix/rdfg-1/Graph>

<http://xmlns.com/foaf/0.1/primaryTopic>

<https://research.tib.eu/covid-19/entity/6by6pzve>

<http://xmlns.com/foaf/0.1/topic>

Anon_0

<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes>

<https://research.tib.eu/covid-19/data/entity/6by6pzve>

<http://purl.org/net/provenance/ns#createdBy>

Anon_1 (more)

expand all